ALNY vs ARWR
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. ARWR: Arrowhead Pharmaceuticals is a clinical-stage biotechnology company leveraging its proprietary RNA interference (RNAi) platform to develop potent medicines that silence disease-causing genes.
Side-by-side fundamentals
| Metric | ALNY | ARWR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $224.53 | $60.74 | |
| Market cap | $30.0B | $8.6B | |
| P/E as of 2026-10-08 | 38.21 | n/a | |
| Net margin FY2025, SEC XBRL | +8.4% | -0.2% | ALNY higher |
| Operating margin FY2025, SEC XBRL | +13.5% | +11.9% | ALNY higher |
| ROE FY2025, SEC XBRL | +39.8% | -0.3% | ALNY higher |
| ROA FY2025, SEC XBRL | +6.3% | -0.1% | ALNY higher |
| Debt / equity as of 2026-09-03 | 2.02 | 2.70 | ALNY lower |
| Revenue growth (YoY) as of 2026-09-03 | +95.1% | +16.9% | ALNY higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | +50.5% | ALNY higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.80 | 1.69 | |
| 1-year return as of 2026-10-08 close | -50.2% | +64.4% | ARWR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.